Clinical Trial, UK
Moving to Phase II
Funxional Therapeutics Ltd (Cambridge, UK) has completed the Phase I programme of its anti-inflammatory compound FX125L, which belongs to the therapeutic class of Broad-Spectrum Chemokine Inhibitors (BSCIs). In its second safety study, the selective chemokine migration inhibitor again provoked no severe adverse effects. The company announced it will go ahead with a Phase II trial in Q2/2010. FX125L is an orally available alpha-aminobicyclolactam derivative that is able to inhibit MCP-I induced leukocyte migration in vitro. The compound, which has a plasma half-life of 25h, is reported to have been taken up quickly. Funxional Therapeutics sees potential for the drug in the broad field of autoimmune diseases such as asthma, rheumatoid arthritis, multiple sclerosis, and disorders with an elevated TNF-alpha level.